



Murdoch
UNIVERSITY

MURDOCH RESEARCH REPOSITORY

This is the author's final version of the work, as accepted for publication following peer review but without the publisher's layout or pagination.

The definitive version is available at

<http://dx.doi.org/10.1016/j.vetpar.2010.11.029>

**Covacin, C., Aucoin, D.P., Elliot, A. and Thompson, R.C.A. (2011)
*Genotypic characterisation of Giardia from domestic dogs in the
USA. Veterinary Parasitology, 177 (1-2). pp. 28-32.***

<http://researchrepository.murdoch.edu.au/4289/>

Copyright: © 2010 Elsevier B.V.

It is posted here for your personal use. No further distribution is permitted.

Accepted Manuscript

Title: Genotypic characterisation of *Giardia* from domestic dogs in the USA

Authors: C. Covacin, D.P. Aucoin, A. Elliot, R.C.A. Thompson



PII: S0304-4017(10)00679-5
DOI: doi:10.1016/j.vetpar.2010.11.029
Reference: VETPAR 5575

To appear in: *Veterinary Parasitology*

Received date: 10-9-2010
Revised date: 11-11-2010
Accepted date: 15-11-2010

Please cite this article as: Covacin, C., Aucoin, D.P., Elliot, A., Thompson, R.C.A., Genotypic characterisation of *Giardia* from domestic dogs in the USA, *Veterinary Parasitology* (2010), doi:10.1016/j.vetpar.2010.11.029

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

1 **Genotypic characterisation of *Giardia* from domestic dogs in the USA**

2

3 **C. Covacin¹, D.P. Aucoin², A. Elliot¹, R.C.A. Thompson^{1*}**

4

5 ¹ WHO Collaborating Centre for the Molecular Epidemiology of Parasitic Infections and
6 the State Agricultural Biotechnology Centre, School of Veterinary and Biomedical
7 Sciences, Murdoch University, South Street, Western Australia 6150, Australia.

8 ² David P Aucoin, ANTECH Diagnostics, Los Angeles, California, USA.

9

10 * Corresponding Author: WHO Collaborating Centre for the Molecular Epidemiology of
11 Parasitic Infections and the State Agricultural Biotechnology Centre, School of
12 Veterinary and Biomedical Sciences, Murdoch University, South Street, Western
13 Australia 6150, Australia. Tel: 08 9360 2466. E-mail: a.thompson@murdoch.edu.au

14

15 **Abstract**

16 The first large-scale urban survey of *Giardia* infections in dogs was undertaken in the
17 USA. It involved several locations in the Western United States with *Giardia* isolates
18 from microscopy-positive samples characterized by multi-locus PCR and sequencing. A
19 high prevalence of *Giardia* was confirmed in asymptomatic domestic dogs, and for the
20 first time, provides evidence that zoonotic assemblages/subgroups of *Giardia* occur
21 frequently in domestic dogs living in urban environments, and more frequently than the
22 dog specific assemblages.

23

24 **Keywords:** *Giardia duodenalis*, domestic dogs, USA, molecular epidemiology

25

26 **Introduction**

27

28 There is increasing evidence globally that infections with *Giardia* occur frequently in
29 domestic dogs, and that it is often the most common enteric parasite of dogs in developed
30 countries (Thompson et al. 2008; Scaramozzino et al. 2009; Ballweber et al. 2010).
31 Prevalence rates vary and are influenced by the sampling strategies and diagnostic
32 methods used (Epe et al. 2010). Although *Giardia* may be associated with gastrointestinal
33 disorders in dogs (Barutzki et al. 2007; Epe et al. 2010), most concern has been directed
34 to the public health significance of such infections since *Giardia* is potentially zoonotic
35 (Thompson 2004; Caccio et al. 2005; Leonhard et al. 2007; Sprong et al. 2009; Ballweber
36 et al. 2010).

37

38 Prevalence rates on their own are insufficient to gauge the public health risks of canine
39 *Giardia* infections without data on the genotypes of *Giardia* that occur in dogs. *G.*
40 *duodenalis* (*G. intestinalis*) is the most frequent form of *Giardia* found in mammals and
41 represents a species complex comprising genotypes/assemblages that are host specific,
42 and those that affect humans and a range of other mammalian species and are thus
43 considered to have zoonotic potential (Monis et al. 2009). Dogs are susceptible to
44 infection with assemblages C and D which are considered to be specific for dogs
45 (Hopkins et al. 1997; Monis et al. 1998; Thompson 2004), while assemblage F seems to
46 be specific for cats, E for livestock (Ey et al. 1997) and G for rats (Monis et al. 1999). In

47 contrast, assemblages A and B affect humans but are not human-specific and infect a
48 wider host range including dogs, cats, livestock and wildlife and are potentially zoonotic.
49 Assemblages A and B show genetic sub-structuring and some subgroups appear to have
50 more zoonotic potential than others (Monis et al. 2009; Sprong et al. 2009).

51

52 Molecular epidemiological studies have been undertaken in different parts of the world
53 and although these have demonstrated that dogs may be infected with zoonotic and/or
54 dog-specific assemblages of *Giardia*, it is not possible to extrapolate from one area to
55 another with respect to the public health risk of canine *Giardia* infections. The frequency
56 of infection with zoonotic assemblages is generally more common in household dogs
57 than in dogs from kennels (Leonhard et al. 2007; Claerebout et al. 2009; Scaramozzino et
58 al. 2009). However, surveys of household dogs have demonstrated differences between
59 geographical areas, with prevalences of infection with zoonotic genotypes varying
60 between 5.5% (Australia), 61% (Thailand), 80.5% (Belgium), 87% and 6.1% (Germany)
61 and 30.8% (Italy) (rev. in Leonhard et al. 2007; Ballweber et al. 2010). The reasons for
62 this variability are not clear but emphasise the need to undertake studies in different
63 geographical areas.

64

65 The public health significance of *Giardia* infections in dogs in the USA has been a
66 subject of concern and controversy for many years yet only one small survey has been
67 published, in which isolates of *Giardia* from 15 domestic dogs in Atlanta were all shown
68 to belong to assemblage D (Sulaiman et al. 2003). The results of this study are surprising
69 in light of the more recent study by Vasilopoulos et al. (2007) which examined 250 cats

70 from Mississippi and Alabama, USA, and of 17 positive for *Giardia* found 6 infected
71 with Assemblage A-I and 11 with Assemblage F (the cat specific genotype), emphasising
72 the need for additional genotyping studies with larger sampling sizes to be undertaken on
73 dogs in the USA.

74

75 Therefore the aim of the present study was to determine the frequency of *Giardia*
76 assemblages in dogs presented at veterinary clinics for health screening in the Western
77 United States where *Giardia* testing incidence is the highest recorded (ANTECH
78 Diagnostics data on file).

79

80 **Materials and Methods**

81

82 *Sampling strategy*

83

84 Samples positive for *Giardia* by microscopy were obtained from 238 healthy dogs
85 presenting for an annual check-up at veterinary clinics in the Western United States. The
86 238 samples for this study were chosen at random on various days in 2009 during which
87 a total of 519,585 faecal samples were submitted and screened at ANTECH laboratories
88 of which 35,172 (6.8%) were positive by microscopy for *Giardia* (ANTECH Diagnostics
89 data on file and available from David.Aucoin@vcaantech.com). All dogs were
90 considered asymptomatic for *Giardia* infection by the veterinarian on duty.

91

92 *DNA extraction*

93 DNA was extracted from faecal samples preserved in ethanol using the Maxwell® 16
94 Tissue DNA Purification Kit (Promega, Madison, USA) with the Maxwell® 16 SEV
95 Instrument (Promega). In addition to the recommended protocol, 1 µl of the final elution
96 was further diluted by adding 4 µl of Water-ultra pure grade (Fisher Biotech Perth,
97 Australia). All PCR reactions were run prior to freezing the extracted DNA.

98 *Amplification of 18S rRNA gene*

99 PCR reactions used 2 µl of the diluted DNA template, 2.5 µl of 10 X Reaction Buffer,
100 2.5 µl of MgCl₂ (25 mM), 0.15 µl Taq-Ti hot start DNA polymerase (Fisher Biotech
101 Perth, Australia), 1 µl of dNTPs (5 mM) (Promega), 1 µl of each primer (10 µM), 5%
102 dimethyl sulfoxide (DMSO)(Sigma-Aldrich St. Louis, Missouri) and Water-ultra pure
103 grade, to a final volume of 25 µl. The first-round PCR conditions were: 96°C for 5 min
104 for 1 cycle, 96°C for 45 s, 50°C for 30 s and 72°C for 45 s for 35 cycles followed by
105 72°C for 7 min. The forward primer RH11, 5'- CATCCGGTCGATCCTGCC -3' and
106 reverse primer RH4, 5'- AGTCGAACCCTGATTCTCCGCCAGG -3' were from
107 Hopkins et al. (1997). Two micro liters from the first-round PCR reaction was used in the
108 second-round PCR. Second-round PCR conditions were: 96°C for 5 min for 1 cycle,
109 96°C for 45 s, 55°C for 30 s and 72°C for 45 s for 35 cycles followed by 72°C for 7min
110 with PCR primers forward GiarF, 5'- GACGCTCTCCCCAAGGAC -3' and reverse
111 primer GiarR, 5'- CTGCGTCACGCTGCTCG -3' (Read et al. 2004). DMSO was used in
112 the first round PCR only. Ultrapure Bovine Serum Albumin (BSA) Non-Aceylated was
113 added to the second round PCR (1% [50mg/mL]).

114 *Amplification of β-giardin gene*

115 PCR reactions used 2 µl of the diluted DNA template, 2.5 µl of 10 X Reaction Buffer,
116 2.5 µl of MgCl₂ (25 mM), 0.15 µl *Tth* Plus DNA polymerase (Fisher Biotech Perth,
117 Australia), 1 µl of dNTPs (5 mM) (Promega), 1 µl of each primer (10 µM) and Water-
118 ultra pure grade (Fisher Biotech Perth, Australia), to a final volume of 25 µl. The first-
119 round PCR conditions were: 95°C for 5 min for 1 cycle, 95°C for 30 s, 50°C for 30 s and
120 72°C for 60 s for 40 cycles followed by 72°C for 7 min. The forward primer G7 5'-
121 AAGCCCGACGACCTCACCCGCAGTGC -3' and reverse primer G759 5'-
122 GAGGCCGCCCTGGATCTTCGAGACGAC -3' were from Cacciò et al. (2002). Two
123 micro liters from the first-round PCR reaction was used in the second-round PCR.
124 Second-round PCR conditions were: 96°C for 5 min for 1 cycle, 96°C for 45 s, 55°C for
125 30 s and 72°C for 45 s for 35 cycles followed by 72°C for 7min with PCR primers
126 forward: 5'- GAACGAACGAGATCGAGGTCCG -3' and reverse: 5'-
127 CTCGACGAGCTTCGTGTT -3', Lalle et al. (2005).

128 *Amplification of Glutamate Dehydrogenase gene (GDH)*

129 PCR reactions used 2 µl of the diluted DNA template, 2.5 µl of 10 X Reaction Buffer,
130 2.5 µl of MgCl₂ (25 mM), 0.2 µl *Tth* Plus DNA polymerase (Fisher Biotech Perth,
131 Australia), 1 µl of dNTPs (5 mM) (Promega), 1 µl of each primer (10 µM) and Water-
132 ultra pure grade (Fisher Biotech Perth, Australia), to a final volume of 25 µl. The first-
133 round PCR conditions were: 94°C for 5 min for 1 cycle, 94°C for 30 s, 50°C for 30 s and
134 72°C for 60 s for 40 cycles followed by 72°C for 7 min. Two micro liters from the first-
135 round PCR reaction was used in the second-round PCR. Cycling conditions for second-
136 round PCR were: 94°C for 5 min for 1 cycle, 94°C for 30 s, 60°C for 30 s and 72°C for

137 60 s for 40 cycles followed by 72°C for 7 min. The primers for the first round PCR,
138 GDHeF, 5'- TCAACGTYAAYCGYGGYTTCCGT -3' and GDHiR 5'-
139 GTTRTCCTTGCACATCTCC -3' as well as the primers for the second PCR reaction
140 GDHiF 5'- CAGTACAACCTCYGCTCTCGG -3' and GDHiR were from Read et al.
141 (2004).

142 *Sequencing*

143 PCR products were purified using a Wizard SV gel and PCR Clean-up system (Promega,
144 Madison, USA) as per the manufacturer's instructions except for the final elution which
145 was reduced from the recommended 50 µl to 20 µl-30 µl. Sequence reactions were
146 performed using the Big Dye Terminator Version 3.1 cycle sequencing kit (Applied
147 Biosystems) according to the manufacturer's instructions. PCR products were sequenced
148 with the second round primers (1µl [10 µM]). The cycling conditions for nucleotide
149 sequencing: 1 cycle of 96°C for 2 min and 25 cycles at 96°C for 10 s, 60°C for 5 s and
150 60°C for 4 min. All PCR and sequencing reactions were run on a TaKaRa Thermal
151 Cyclier Dice™ Version III. Reactions were electrophoresed on an ABI 3730 48 capillary
152 machine.

153 Sequences were analysed and contigs of nucleotide sequences were made using
154 Sequencher 4.8 (Gene Codes, Ann Arbor, MI, USA). Sequences were compared with
155 sequences in GenBank by BLAST searches (<http://www.ncbi.nlm.nih.gov/BLAST/>,
156 Altschul et al. 1997). In addition to the BLAST search, sequences were aligned in
157 sequencher with sequences from GenBank with known sub-assembly information to

158 confirm the sub-assemblage genotype and to determine the presence of multiple
159 genotypes (Table 1).

160

161 **Results**

162

163 Of the 238 samples that were found microscopy positive in ANTECH laboratories prior
164 to shipment to Australia, 148 were positive by PCR, of which 128 samples provided
165 interpretable sequence data. Of these 128 samples, it was possible to identify a total of
166 296 *Giardia* infections of which 15% were assemblage C, 16% assemblage D, 28%
167 assemblage A, and 41% assemblage B (Figure 1, Table 2).

168

169 Multiple genotypes were amplified from 83% of the 128 samples. Results for 57% of the
170 multiple genotypes were from two or more loci, 25% of these amplifications from
171 different loci provided the same genotype result. Sub-genotypes identified with the β -
172 giardin gene were from assemblage A, sub-genotypes A2, A3, A5, A8, and for
173 assemblage B, B1, B2, B3 and B4 (Table 2).

174

175 18S preferentially amplified assemblages B, D and C whereas β -giardin preferentially
176 amplified assemblages A, B (Table 2). β -giardin appeared to be more sensitive
177 amplifying single and multiple infections (Figure 1). The glutamate dehydrogenase gene
178 (GDH) provided limited results with genotype information for only 17 samples (Table 2).

179

180

181

182 **Discussion**

183

184 The present study is the first large-scale urban survey of *Giardia* infections in dogs
185 undertaken in the USA. It involved several locations in the Western United States and has
186 not only confirmed the high prevalence of *Giardia* in asymptomatic domestic dogs, but
187 has also shown, for the first time, that zoonotic assemblages/subgroups occur frequently
188 in domestic dogs living in urban environments, and more frequently than the dog specific
189 assemblages.

190

191 Multiple infections with zoonotic assemblages were most common, followed by mixed
192 infections with zoonotic and dog assemblages, followed by single infections with B, C or
193 D (Table 2). The results from this study emphasize that it is not possible to extrapolate
194 from one geographical region to another in terms of the prevalence or assemblage
195 composition of *Giardia* infections in dogs. These results thus support the global picture
196 for *Giardia* in dogs compiled by Ballweber et al. (2010). Furthermore, our study found a
197 higher frequency of *Giardia* infections with assemblage B than assemblage A, which has
198 not been reported elsewhere. This suggests that in North America at least, we cannot
199 assume that, as in Europe (Sprong et al. 2009) assemblage B has a predominantly human
200 distribution. We also found the β -giardin subgroups, A2, A3, B1, B3 and B4 in dogs,
201 which have been reported previously in humans (Lalle et al. 2005) but not before in dogs,
202 thus highlighting their zoonotic potential.

203

204 The high frequency of multiple/mixed infections found in this study has been
205 increasingly reported from multilocus studies in other countries in both humans and dogs
206 (e.g., Hussein et al. 2009; Sprong et al. 2009). This may be due to meiotic recombination
207 or preferential amplification of one assemblage over another in mixed infections (Caccio
208 et al. 2005, Cooper et al. 2007, Teodorovic et al. 2007, Weilinga and Thompson, 2007;
209 Lasek-Nesselquist et al. 2009). As regards true mixed infections, it raises the question as
210 to their source. It is possible that some infections are more commonly acquired as puppies
211 (e.g. the dog assemblages) and others possibly later in life as contact with other potential
212 hosts, both dog and human, increases, as does exposure to varied environments. The
213 occurrence of mixed infections also raises the intriguing question of how long do
214 individual infections persist and whether one assemblage may eventually outcompete
215 another?

216

217 Of the 238 samples that were found microscopy positive in ANTECH laboratories prior
218 to shipment to Australia, 148 were positive by PCR, of which 128 samples provided
219 interpretable sequence data. The lower number of PCR-positives compared to microscopy
220 is probably a result of the poor condition of some samples following shipment. PCR-
221 inhibition is also a possible reason for unsuccessful amplification, however, in this study
222 DNA was extracted using the Maxwell® 16 SEV Instrument (Promega) with the final
223 elution further diluted to dilute the inhibitors. This method was successful when tested on
224 known positive samples in our laboratory.

225

226 Although PCRs for three loci were run on all samples, the glutamate dehydrogenase gene

227 provided limited results with genotyping data for only 17 samples. Amplification of the
228 18S locus is robust and useful for determining the presence or absence of an infection, the
229 short sequence does not provide sub-assembly information, in contrast to β -giardin
230 appeared to be more sensitive in amplifying single and multiple infections (Figure 1). We
231 considered that all genotypes amplified were present in an individual sample whether it
232 was supported or differed to another locus. We could not determine if the difference in
233 the genotypes from the different loci was due to sensitivity or preferential amplification
234 of a loci.

235

236

237 The results demonstrate that a significant proportion of asymptomatic dogs in urban areas
238 of the USA harbour zoonotic *Giardia*, and should therefore be considered a potential
239 reservoir for infection in humans. All assemblages can be transmitted in cycles where
240 only dog to dog transmission occurs, but humans may be involved in a zoonotic cycle of
241 transmission with assemblages A and B, either contracting infection from dogs, or acting
242 as a source of infection for dogs.

243

244 **References**

245

246 Ballweber, L.R., Xiao, L., Bowman, D.D., Kahn, G., Cama, V.A. 2010. Giardiasis in
247 dogs and cats: update on epidemiology and public health significance. Trends Parasitol.
248 26, 180-189.

249

- 250 Barutzki, D., Thompson, R.C.A., Wielinga, C., Parker, U., Schaper, R. 2007.
251 Observations on *Giardia* infection in dogs from veterinary clinics in Germany. Parasitol.
252 Res. 101, 153-156.
253
- 254 Caccio, S. M., Thompson, R. C. A., Mclachin, J., Smith, H. V. 2005. Unravelling
255 *Cryptosporidium* and *Giardia* epidemiology. Trends Parasitol. 21, 430-437.
256
- 257 Claerebout, E., Casaert, S., Dalemans, A.-C., De Wilde, N., Levecke, B., Vercruyse, J.,
258 Geurden, T. 2009. *Giardia* and other intestinal parasites in different dog populations in
259 Northern Belgium. Vet. Parasitol. 161, 41-46.
260
- 261 Cooper, M. A., Adam, R. D., Worobey, M., Sterling, C. R. 2007. Population genetics
262 provides evidence of recombination in *Giardia*. *Current Biol.* 17, 1984-1988.
263
- 264 Epe, C., Rehker, G., Lorentzen, L. 2010. *Giardia* in symptomatic dogs and cats in
265 Europe - results of a European study. Vet. Parasitol (in press).
266
- 267 Ey, P.L., Mansouri, M., Kulda, J., Nohýnková, E., Monis, P.T., Andrews, R.H.,
268 Mayrhofer, G., 1997. Genetic analysis of *Giardia* from hoofed farm animals reveals
269 artiodactyls-specific and potentially zoonotic genotypes. J. Euk. Microbiol. 44, 626-635.
270
- 271 Hopkins, R.M., Meloni, B.P., Groth, D.M., Wetherall, J.D., Reynoldson, J.D., Thompson,
272 R.C.A., 1997. Ribosomal RNA sequencing reveals differences between the genotypes of

273 *Giardia* isolates recovered from humans and dogs living in the same locality. J. Parasitol,
274 83, 44-51.

275

276 Hussein, A.I.A., Yamaguchi, T., Nakamoto, K., Iseki, M., Tokoro, M. 2009. Multiple-
277 subgenotype infections of *Giardia intestinalis* detected in Palestinian clinical cases using
278 a subcloning approach. Parasit. Intl. 58, 258-262.

279

280 Lalle, M., Pozio, E., Capelli, G., Bruschi, F., Crotti, D. & Caccio, S. M. (2005) Genetic
281 heterogeneity at the B-giardin locus among human and animal isolates of *Giardia*
282 *duodenalis* and identification of potentially zoonotic subgenotypes. *Int. J. Parasitol.* 35,
283 207-213.

284

285 Lasek-Nesselquist, E., Welch, D.M., Thompson, R.C.A, Steuart, R.F., Sogin, M.L. 2009.
286 Genetic exchange within and between assemblages of *Giardia duodenalis*. J. Eukaryot.
287 Microbiol. 56, 504-518.

288

289 Leonhard, S., Pfister, K., Beelitz, P, Thompson, R. C. A. 2007. The molecular
290 characterisation of *Giardia* from dogs in southern Germany. Vet. Parasitol. 150, 33-38.

291

292 Monis, P.T., Andrews, R.H., Mayrhofer, G., Mackrill, J., Kulda, J., Isaac-arenton, J.L., Ey,
293 P.L. 1998. Novel analysis of *Giardia intestinalis* identified by genetic analysis of
294 organisms isolated from dogs in Australia. Parasitology 116, 7-19.

295

- 296 Monis, P.T., Andrews, R.H., Mayrhofer, G., Ey, P.L. 1999. Molecular systematics of the
297 parasitic protozoan *Giardia intestinalis*. Mol. Biol. Evol. 16, 1135-1144.
298
- 299 Monis, P. T., Caccio, S. M., Thompson, R. C. A. 2009. Variation in *Giardia*: towards a
300 taxonomic revision of the genus. Trends Parasitol. 25, 93-100.
301
- 302 Read, C. M., Monis, P. T., Thompson, R. C. A. 2004. Discrimination of all genotypes of
303 *Giardia duodenalis* at the glutamate dehydrogenase locus using PCR-RFLP. Inf., Gen.
304 Evol. 4, 125-130.
305
- 306 Scaramozzino, P., Di Cave, D., Berrilli, F., D'Orazi, C.D., Spaziani, A., Mazzanti, S.,
307 Scholl, F., De Liberato, C.D. 2009. A study of the prevalence and genotypes of *Giardia*
308 *duodenalis* infectiong kennelled dogs. Vet. J. 182, 231-234.
309
- 310 Sprong, H., Caccio, S.M., van der Giessen, J.W.B. 2009. Identification of zoonotic
311 genotypes of *Giardia duodenalis*. Plos Negl. Trop. Dis. 3, e558.
312
- 313 Sulaiman, I.M., Fayer, R., Bern, C., Gilman, R.H., Trout, J.M., Schantz, P.M., Das, P.,
314 Lal, A.A., Xiao, L., 2003. Triosephosphate isomerase gene characterization and potential
315 zoonotic transmission of *Giardia duodenalis*. Emerg. Infect. Dis. 9, 1444-1452.
316
- 317 Teodorovic, S., Braverman, J. M., Elmendorf, H. G. 2007. Unusually low levels of
318 genetic variation among *Giardia lamblia* isolates. Euk. Cell 6, 1421-1430.

319

320 Thompson, R. C. A. (2000) Nomenclature and genetic groupings of *Giardia* infecting
321 mammals. *Parasitol. Today* 16, 210-213.

322

323 Thompson, R.C.A. 2004. The zoonotic significance and molecular epidemiology of
324 *Giardia* and giardiasis. *Vet. Parasitol.* 126, 15-35.

325

326 Thompson, R.C.A., Palmer, C.S. and O'Handley, R. 2008. The public health and
327 clinical significance of *Giardia* and *Cryptosporidium* in domestic animals. *Vet.*
328 *J.* 177, 18-25.

329

330 Vasilopoulos, R.J., Rickard, L.G., Mackin, A.J., Pharr, G.T., Huston, C.L. 2007.

331 Genotypic analysis of *Giardia duodenalis* in domestic cats. *J. Vet. Intern. Med.* 21, 352-
332 355.

333

334 Weilinga, C., Thompson, R. C. A. 2007. Comparative evaluation of *Giardia duodenalis*
335 sequence data. *Parasitology* 134, 1795-1821.

336

337

338

339

340

341

342

343 **Table 1.** GenBank accession numbers for contigs for the three loci.

344

<i>18S rRNA gene</i>	<i>β-giardin gene</i>	<i>Glutamate dehydrogenase gene</i>
AF199443-D	AY072728-B	AF069059-B111
AF199444-F	AY545643-A	AY178750-BIV
AF199445-A1	AY545645-A11	AY826193-B
AF199446-A11	AY545646-C	DQ414242-A1
AF199447-B (111)	AY545648-D	L40510-A11
AF199448-E	AY545649-A1	U60982-C
AF199449-C	AY545649-A8	U60986-D
AF199450-G	AY647266-B	
DQ157272-E	DQ466724-30-A1	
M54878-A1	EU189375-E	
U09491-B	FJ009206-C	
U09492-B	P201207-A2	

345

346

347

348

349

350

351

352 **Table 2.** Assemblage and Sub-assemblage information for 128 samples for one, two or
 353 three loci.

<i>18S</i>	GDH	β <i>giardin</i>	<i>18S</i> and GDH	<i>18S</i> and β <i>giardin</i>	<i>18S</i> , GDH and β <i>giardin</i>
B (8)	C (5)	A2, A5 (1)	B, C/D - C/D (1)	B - A2 (2)	B - C - A2 (1)
B, C/D (1)		A2, B1 (6)	B - C (9)	B - A2, B1 (1)	
B, D (1)		A2, B3 (4)	B/C - B/C (1)	B - A5, B3 (1)	
C (3)		A2, B4 (9)	B/C - C (1)	B - B (1)	
C/D (1)		A3, B1 (2)		B - B1 (2)	
		A3, B4 (1)		B - D (1)	
		A5, B3 (1)		B, C/D - B (1)	
		A5, B4 (2)		C - A2 (1)	
		A8, B1 (1)		C - A2, B1 (2)	
		A8, B2 (1)		C - A2, B4 (3)	
		A8, B4 (1)		C - A3, B4 (2)	
		B1 (3)		C - A5, B4 (1)	
		B1, A2 (2)		C - A8, B3 (1)	
		B1, A8 (1)		C - D (1)	
		B1, B3 (1)		C - D/C, A2 (1)	
		B4, A5 (1)		C/D - A2, B3 (1)	
		B, A3 (1)		C/D - C/D, B3 (1)	
		C, A2, B1 (1)		D - A2, B3 (9)	
		C, A2, B4 (1)		D - A2, B4 (7)	
		D (2)		D - A3, B4 (1)	
		D, A2, B3 (1)		D - A5, B3 (1)	
		D, A2, B4 (1)		D - A8, B2 (1)	
		D, A3, B3 (1)		D - A8, B3 (1)	

D, A3, B4 (1)	D - B1 A2 (1)
D, A8 (1)	D - B1, B3 (1)
D, A8, B3 (1)	D - C, A2, B4 (1)
D, B1 (1)	D - D, B A2 (1)

354 Results in the columns labelled with the single locus are from samples which only
355 amplified at this locus, for example the 18S column has results for 14 samples, which
356 only amplified, at this locus (18S) and the GDH column has results for five samples
357 which only amplified for GDH. Columns with two and three loci have results for samples
358 with sub assemblage information at more than one locus, for example 18S and GDH or
359 18S and *β giardin*. The dash between the letters separates the loci information. For
360 example in the column labelled 18S and *β giardin* the first sample is B-A2 (2), indicates
361 this sample had assemblage B for 18S and sub-assemblage A2, for *β giardin*. The 2 in
362 parentheses indicate there were two samples with this result. A comma between letters
363 e.g. A8, B2 indicates that both genotypes were found in a sample, results written C/D
364 indicates it may have been either C or D.

365

366

367

368

369

370

371

372

373

374

375 Figure 1

376 Sequencing results for *β giardin*. A single peak at a known SNP site indicates a single

377 genotype and possibly a single infection, however two or three peaks may indicate the

378 presence of multiple infections. Samples labeled 238, and 234 have three peaks at a

379 single site.

380

381

382

383

384

385

386

387

388

389

390

391


392

393

394

395

396



396
397
398

ACCEPTED MANUSCRIPT